NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on NAMS stock, giving a Buy rating on January 9.

Matt Phipps has given his Buy rating due to a combination of factors that collectively strengthen the investment case for NewAmsterdam Pharma. He highlights that blinded cardiovascular event rates in the pivotal PREVAIL outcomes trial are unfolding in a pattern very similar to the earlier BROADWAY study, including a notable uptick in events around the six‑month mark, which supports robust statistical power. Given the overlap in timing, patient characteristics, and geographies between PREVAIL and BROADWAY, he views these parallels as reinforcing the likelihood that PREVAIL can reproduce an approximate 20% reduction in major cardiovascular events, a result that would be clinically meaningful and commercially attractive. He also points out that trial conduct metrics are favorable, with limited use of competing therapies such as GLP‑1s, SGLT2 inhibitors, and PCSK9 inhibitors and low discontinuation rates, which should help preserve the integrity of the efficacy signal.

Furthermore, Phipps notes that management’s updated guidance and mid‑2026 median follow‑up expectations provide better visibility into the clinical and regulatory timeline, reducing some development risk and helping investors better frame key catalysts. He also emphasizes the contribution of the RUBENS Phase III program, designed to expand the label into an important diabetes population without established atherosclerotic cardiovascular disease, which could significantly broaden the addressable market. The combination of encouraging PREVAIL event‑rate dynamics, disciplined trial execution, and multiple upcoming milestones across 2026 underpins his conviction that the risk/reward profile remains attractive at current levels. Taken together, these clinical, strategic, and timing factors support his conclusion that NewAmsterdam Pharma’s shares warrant a Buy recommendation.

According to TipRanks, Phipps is a 4-star analyst with an average return of 6.6% and a 49.04% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Incyte, and Bristol-Myers Squibb.

In another report released on January 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $52.00 price target.